# ACCESS (NCT04904588)

> HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04904588
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Center for International Blood and Marrow Transplant Research
- Conditions: Acute Lymphoblastic Leukemia; Acute Myelogenous Leukemia; Mixed Phenotype Acute Leukemia; Acute Leukemia; Myelodysplastic Syndromes; Chronic Myelogenous Leukemia; Chronic Lymphocytic Leukemia; Lymphoma
- Interventions: Busulfan; Busulfan; Fludarabine; Total-body irradiation; Cyclophosphamide; Melphalan; PBSC Hematopoietic Stem Cell Transplantation (HSCT); Bone Marrow Hematopoietic Stem Cell Transplantation; Post-transplant Cyclophosphamide; Mesna; Tacrolimus; Mycophenolate Mofetil; Patient-Reported Outcomes
- Enrollment: 300
- Primary outcome: Overall Survival

## HCP commentary on ACCESS so far

What clinicians have said in podcasts, YouTube videos and X posts we have indexed. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- Bluesky threads: 2
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=access-nct04904588